As per our research report, the size of the MEA Adhesion Barrier Market is predicted to value USD 80.50 million in 2021 and USD 104.72 million by 2026, witnessing a CAGR of 5.4% during the forecast period due to an increase in the volume of surgeries along with sports injuries which are driving the growth of the market.
Y-O-Y growth in the incidence of Neurological, Gynecological, Ophthalmic, and Heart Disorders in the MEA region is expected to drive the market growth. According to the World Heart Association, 7.6million people suffer from circulatory and heart disease. Heart and circulatory disease accounted for around 27% of all deaths in the Middle East regions in 2020. Therefore, treatment for these disorders requires surgery at times, increasing the demand for barriers to adherence.
In addition, the increase in healthcare expenditure associated with the increasing FDA approval for various adhesion barrier products is also increasing the market's growth. Moreover, favorable reimbursement policies and growing awareness of various surgical procedures drive market growth during the forecast period. Furthermore, the rapid growth of the geriatric population, the epidemiological shift from infectious diseases to chronic diseases, the increase in life expectancy, the expansion of private sector hospitals in rural areas, and the increased demand for surgical procedures drive the demand for surgical interventions.
Surgeons believe they can cost-effectively reduce the risk of postoperative complications in patients through adhesion barriers. Hence, these new advancements are expected to drive the MEA adhesion barrier market growth in the forecasted period.
The growth of the MEA adhesion barrier market is further expected to be driven by the increasing number of gynecological laparoscopic procedures. Moreover, the increasing adoption of gel form and film form in various gynecological procedures, including endometriosis surgery, ovarian cystectomy, and ectopic pregnancy, is driving the market's growth. The slow adoption of minimally invasive techniques in developing countries is expected to impact the adoption of barriers to membership positively. Minimally invasive surgeries require expensive equipment, such as cameras and robot-assisted devices. Adoption of these devices is expected to be moderate in developing countries due to price-sensitive customers.
With the increased risk of postoperative adherence, the market still faces barriers in accessibility, lack of health education, and lack of awareness of the importance of treatment. Although surgeons are aware of these risks, they are reluctant to use adhesion barriers due to the lack/reliable and limited clinical evidence supporting the safety and efficacy of marketed adhesion barrier products. In addition, due to issues related to the safety and effectiveness of adhesion barriers, companies are having difficulty obtaining marketing authorizations for their products. Additionally, in recent years the market has seen the discontinuation of approved adhesion barrier products due to poor clinical outcomes.
The limited applications of certain types of adhesion barrier products and the high cost of major surgical procedures are some of the factors that are expected to hamper the market's growth.
This research report on the MEA adhesion barrier market has been segmented and sub-segmented into the following categories:
By Product Form:
By Surgical Application:
Geographically, the MEA adhesion barrier market is expected to showcase a sluggish growth rate during the forecast period due to the increase in the geriatric population and the increase in the incidence of heart and neurosurgery, which require surgeries. In addition, growing private sector investments in healthcare and rapidly expanding medical tourism are expected to boost the market in the region. As a result, most of the regions of Saudi Arabia, Turkey, the United Arab Emirates, and Kuwait are expected to contribute to maximum growth of the region during the forecast period.
KEY MARKET PLAYERS:
Baxter International Inc., Medtronic Plc., C. R. Bard, Inc., Johnson & Johnson, Sanofi Group, Atrium Medical Corporation, Integra Lifesciences Corporation, Anika Therapeutics Inc., FzioMed, Inc., and MAST Biosurgery AG are some of the companies playing an active role in the MEA adhesion barrier market.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Synthetic Adhesion Barriers
220.127.116.11 Regenerated Cellulose
18.104.22.168 Hyaluronic Acid
22.214.171.124 Polythene Glycol
5.1.3 Natural Adhesion Barriers
126.96.36.199 Collagen & Protein
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Product Form
5.2.2 Film Adhesion Barriers
5.2.3 Gel Adhesion Barriers
5.2.4 Liquid Adhesion Barriers
5.2.5 Y-o-Y Growth Analysis, By Product Form
5.2.6 Market Attractiveness Analysis, By Product Form
5.2.7 Market Share Analysis, By Product Form
5.3 Surgical Applications
5.3.2 Gynaecological Surgeries
5.3.3 Cardiovascular Surgeries
5.3.4 Neurological Surgeries
5.3.5 Orthopaedic Surgeries
5.3.6 General/Abdominal Surgeries
5.3.7 Urological Surgeries
5.3.8 Reconstructive Surgeries
5.3.9 Other Surgeries
5.3.10 Y-o-Y Growth Analysis, By Surgical Applications
5.3.11 Market Attractiveness Analysis, By Surgical Applications
5.3.12 Market Share Analysis, By Surgical Applications
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Product Form
18.104.22.168 By Surgical Applications
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Product Form
184.108.40.206 By Surgical Applications
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Product Form
126.96.36.199 By Surgical Applications
6.2 Middle East
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxter International Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Medtronic Plc.
8.3 C. R. Bard, Inc.
8.4 Johnson & Johnson
8.5 Sanofi Group
8.6 Atrium Medical Corporation
8.7 Integra Lifesciences Corporation
8.8 Anika Therapeutics Inc.
8.9 FzioMed, Inc.
8.10 MAST Biosurgery AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures